Patient-derived Xenografts (PDXs) are considered as relevant preclinical model for anticancer drug development due to original recapitulation of patient genetic profile, gene expression patterns and tissue histology. In this study, we investigated combination efficacy of CDODA-Me (Methyl 2-cyano-3,11-dioxo-18-olean-1,12-dien-30-oate) and TKI inhibitor Erlotinib (ERL) against Lung NSCLC PDX spheroids and 3D bioprinted PDX cells.
This review focuses on developments in the field of bioprinting for musculoskeletal tissue engineering, along with discussion on the various approaches for bone, cartilage and connective tissue fabrication. All approaches (cell-laden, cell-free and a combination of both) aim to obtain complex, living tissues able to develop and mature, using the same fundamental technology.
The three-dimensional (3D) bioprinting technology allows creation of 3D constructs in a layer-by-layer fashion utilizing biologically relevant materials such as biopolymers and cells. The aim of this study is to investigate the use of 3D bioprinting in a clinically relevant setting to evaluate the potential of this technique for in vivo chondrogenesis.
Successful bioprinting of hydrogels relies on geometric accuracy and cell viability, both of which are influenced by a number of variable printing parameters. Despite much research aimed at the resulting quality of bioprinted structures, there is no standard method of comparing bioprint results. In this study, we have developed a simple method of assessing the bioprint results from a range of printing parameters in a standardized manner applicable to extrusion-based bioinks.
Our Cellink Diamond Partners are hand selected by us in order to achieve well rounded and synergical partnerships in the life science industry.
Are you interested in becoming a Diamond Partner? Please fill in the application form below.
Complete the application form if you want to apply for partnership. Name and E-mail fields are mandatory.